The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 08, 2013
Filed:
Jun. 23, 2005
Qiang Ding, Beijing, CN;
Nathanael Schiander Gray, Boston, MA (US);
Bing LI, Northborough, MA (US);
Yi Liu, San Diego, CA (US);
Taebo Sim, Seoul, KR;
Tetsuo Uno, San Diego, CA (US);
Guobao Zhang, San Diego, CA (US);
Carole Pissot Soldermann, Village-Neuf, FR;
Werner Breitenstein, Basel, CH;
Guido Bold, Gipf-Oberfrick, CH;
Giorgio Caravatti, Bottmingen, CH;
Pascal Furet, Thann, FR;
Vito Guagnano, Basel, CH;
Marc Lang, Mulhouse, FR;
Paul William Manley, Basel, CH;
Joseph Schoepfer, Riehen, CH;
Carsten Spanka, Lorrach, DE;
Qiang Ding, Beijing, CN;
Nathanael Schiander Gray, Boston, MA (US);
Bing Li, Northborough, MA (US);
Yi Liu, San Diego, CA (US);
Taebo Sim, Seoul, KR;
Tetsuo Uno, San Diego, CA (US);
Guobao Zhang, San Diego, CA (US);
Carole Pissot Soldermann, Village-Neuf, FR;
Werner Breitenstein, Basel, CH;
Guido Bold, Gipf-Oberfrick, CH;
Giorgio Caravatti, Bottmingen, CH;
Pascal Furet, Thann, FR;
Vito Guagnano, Basel, CH;
Marc Lang, Mulhouse, FR;
Paul William Manley, Basel, CH;
Joseph Schoepfer, Riehen, CH;
Carsten Spanka, Lorrach, DE;
Novartis AG, Basel, CH;
IRM LLC, Hamilton, BM;
Abstract
The invention relates to compounds of formula (I) wherein the substituents X, R, R, Rand Rhave the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.